BAUSCH & LOMB CORP

Drug pipeline (81)

Asset	Stage	Revenue	Trials	Status
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE	approved	—	0	—
ALAWAY	approved	—	1	approved
ALREX	approved	—	13	approved
ATROPINE SULFATE	approved	—	0	—
BACITRACIN ZINC AND POLYMYXIN B SULFATE	approved	—	0	—

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (122)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT05360784	phase3	completed	2022-05-13	2022-11-23	Bausch & Lomb Incorporated	"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"
NCT00198523	phase3	completed	2005-07-01	2005-10-01	Bausch & Lomb Incorporated	A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte
NCT01212471	phase3	completed	2010-09-01	2011-08-01	Bausch & Lomb Incorporated	A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
NCT00595101	phase2	completed	2007-12-01	2008-06-01	Bausch & Lomb Incorporated	A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.
NCT03489941	phase3	completed	2018-04-07	2018-04-29	Bausch & Lomb Incorporated	A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle

FDA applications (87)

Application

Approved

Type

Applicant

Products

NDA 218424

2024-04-19

NDA

BAUSCH AND LOMB INC

NDA 216675

2023-05-18

NDA

BAUSCH AND LOMB INC

NDA 213581

2022-03-15

NDA

BAUSCH AND LOMB INC

NDA 211950

2021-10-22

NDA

BAUSCH AND LOMB INC

ANDA 204884

2021-08-18

ANDA

BAUSCH AND LOMB INC